CinCor Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

22.03.2022 - BrigHtn Phase 2 study with CIN-107 for Resistant Hypertension Enrollment Complete with Topline Results Expected in 2H 2022 Topline Data from HALO Phase 2 study with CIN-107 for Uncontrolled Hypertension Expected in 2H 2022 Mason Freeman, M.D. ...

Related Keywords

Boston ,Massachusetts ,United States ,American ,Terry Coelho ,June Lee ,Jason Pitts ,Troy Ignelzi ,Mason Freeman ,John Thero ,Bob Yedid ,Masonw Freeman ,American Heart Association ,American College Of Cardiology ,Nasdaq ,Exchange Commission ,Development Rd Expenses ,Myokardia Inc ,Amarin Corporation ,Management Team ,Cincor Pharma Inc ,Business Development ,Chief Medical ,Cor Pharma ,Marc De Garidel ,Chief Executive ,Executive Vice President ,Chief Financial Officer ,Chief Business Development Officer ,Recent Corporate ,Htn Phase ,Brightn Phase ,First Patient ,Executive Management ,Chief Medical Officer ,Clinical Development ,Chief Executive Officer ,Karuna Therapeutics ,General Atlantic ,Esker Therapeutics ,Planned Phase ,Comprehensive Loss ,American College ,